PEPTONIC Aktie

 

The annual general meeting in PEPTONIC medical AB (the "Company") was held today, 26 June 2025, at Eversheds Sutherland Advokatbyrå's premises at Sveavägen 20 in Stockholm. The following main resolutions were passed with the required majority at the meeting. Adoption of the income statement and balance sheet  The meeting adopted the income statement and balance sheet as included in the annual report for 2024. Allocation of results The meeting resolved that the Company's results shall be allocated in accordance with the board's proposal in the annual report. No dividend will be paid...

On 23 May 2025, PEPTONIC medical AB (“Peptonic” or the “Company”) issued a notice to the annual general meeting to be held on 26 June 2025. The notice to the annual general meeting proposed that the board of directors should consist of four (4) ordinary board members without deputies and that the nomination committee intended to present proposals for board members as soon as possible. In light of this, the Company is publishing the nomination committee's proposals for board members. Item 11 - Election of board members and any deputy board members The nomination committee proposes that...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has today, June 17 2025, approved the Company's request to extend the ongoing company reconstruction by three months, until 15 September 2025. The extension is in line with the previously communicated timeline and aims to allow finalization of a reconstruction plan and the initiation of plan proceedings in accordance with the Swedish Company Reconstruction Act. Uppsala District Court has today approved the Company's request to extend the ongoing company reconstruction by three months, until 15...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today submitted a request to the Uppsala District Court to extend the ongoing company reconstruction by three months, through 13 September 2025. The request is supported by the Company's appointed reconstruction administrator. The reason for the extension is that the Company, together with the administrator, is in the process of finalizing a reconstruction plan. The intention is to submit this plan to the court for formal proceedings within the extended period, subject to the court's approval of the extension. Request for Extension...

In Peptonic Medical's annual report for 2024, there was a remark in the audit report: "We draw attention to the administration report, which states that the company has reported losses for several years in a row and under the heading "Earnings capacity, future capital requirements and continued operations" in the administration report and Note 2, it is stated that the company has strained liquidity, that liquidity is assessed as insufficient and that the company applied for corporate reconstruction in March 2025. These circumstances indicate that there are material uncertainties that may lead...

The 2024 Annual report of Peptonic Medical AB (publ) is now available on the company website. The annual report is available in Swedish in PDF format on the company website at: https://www.peptonicmedical.se/en/financial-information/ For further information please contact: Anna Linton, CEO of Peptonic Medical AB E-mail: anna.linton@peptonicmedical.se Phone: +46 70-244 92 07 About PEPTONIC medical AB PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health....

PEPTONIC medical AB (publ) (the “Company”) has, as previously communicated, applied for and been granted corporate restructuring by the Uppsala District Court. At the creditors' meeting on 26 March 2025, the District Court decided that the corporate restructuring may continue until 13 June 2025. During the three initial months of the corporate restructuring, the Company has made progress regarding previously communicated restructuring measures and will, in connection with the Company's submission of a request for extension of the restructuring, report on these. A corporate restructuring may...

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting in PEPTONIC medical AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall prevail. The shareholders of PEPTONIC medical AB, reg. no. 556776-3064 (the "Company" or "Peptonic"), are hereby invited to the annual general meeting on 26 June 2025 at 10.00 a.m. at Eversheds Sutherland Advokatbyrå's premises, Sveavägen 20 in Stockholm. Registration will commence at 09.45 am CEST. RIGHT TO PARTICIPATE AND NOTICE OF...

Correction of the press release published on 7 May 2025 regarding the resolution from the extraordinary general meeting on 7 January 2025 on the reduction of share capital and reverse share split where the registered share capital was incorrect. The correct share capital and number of shares are stated below. Shares and share capital The board's decision thus means that the registered share capital continues to amount to SEK 42,952,081.9244 divided into 9,337,409,114 shares, each share with a quota value of SEK 0.0046. For further information please contact: Anna Linton, CEO of...

As communicated in the notice to the extraordinary general meeting on 28 November 2024, two proposals were submitted for a reduction of the share capital - one of which required authorization from the Swedish Companies Registration Office - as well as a proposal to amend the articles of association to implement a reverse share split. The bulletin published on 7 January 2025, shows that the resolutions were voted through. In light of the ongoing company reorganization, and in consultation with the administrator and all shareholders who voted in favour of the resolutions, the board of directors...

The Board of Directors of Peptonic Medical AB (publ.) ("Peptonic" or the "Company") has decided to postpone the publication of its interim report for the first quarter of 2025. The interim report will be published on May 28, 2025, instead of the previously communicated date of May 7, 2025. The reason is that the Company needs additional time to complete the report, taking into account the ongoing corporate restructuring. Peptonic is working purposefully to strengthen the company's financial position. The interim report will provide an update on developments during the period, including...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. PEPTONIC medical AB ("Peptonic" or the "Company") announces that the rights issue which the board of directors resolved on November 28, 2024, and was approved at the extra general meeting...

As communicated through a press release on March 11, 2025, the board of directors of PEPTONIC Medical AB (publ) (the "Company") decided to submit an application for corporate restructuring to Uppsala District Court and on March 13, 2025, the district court decided on corporate restructuring regarding the Company. At the creditors' meeting on March 26, 2025, the district court decided that the corporate restructuring may continue. Preliminary restructuring measures The Company, together with the administrator, has prepared the following preliminary restructuring measures: · Offer...

As part of its growth strategy in the US market, Peptonic Medical AB (publ) ("Peptonic" or the "Company") has established a new wholly-owned subsidiary, Peptonic Medical Inc. This new entity will be responsible for direct sales of the Company's personal care products within the intimate health sector, including both existing offerings and future product launches. The establishment of Peptonic Medical Inc. is a strategic move aimed at strengthening the Company's presence in the US market. By creating a dedicated subsidiary with a sole focus on direct sales under Peptonic's own brand, the...

Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the press release issued on March 14, 2025, titled "Court of Appeal convicts former employees – Peptonic Medical AB ordered to pay corporate fine", was mistakenly labeled under the EU Market Abuse Regulation (MAR). As the ruling was already public, the information is not subject to MAR. The press release concerned the Court of Appeal's conviction of two former employees for aggravated insider trading related to their actions in connection with a financing arrangement in the spring of 2019. These events have no connection...

Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the Court of Appeal has overturned the District Court's acquittal in the insider trading case involving events from the spring of 2019 and individuals from the Company's former management. The Court of Appeal has found the former employees guilty of aggravated insider trading, and consequently, the Company being imposed with a corporate fine of SEK 500,000. The ruling pertains to an investigation into aggravated insider trading related to a financing arrangement in the spring of 2019, in which the convicted former...

Peptonic Medical AB (publ.) ("Peptonic" or "the Company") announces that the Uppsala District Court has approved the Company's application for corporate restructuring. This decision enables Peptonic to implement the necessary restructuring to establish a stable and profitable business. The Uppsala District Court has today approved Peptonic's application for corporate restructuring. The Company's primary focus is now to ensure that business operations remain uninterrupted.  Discussions will be initiated with suppliers and business partners to maintain strong and ongoing collaboration....

The Board of Directors of Peptonic Medical AB (publ.) ("Peptonic" or "the Company") has today decided to submit an application for corporate restructuring. This decision is an extraordinary measure following a prolonged liquidity challenge and is intended to create the conditions for a stable and profitable business. External consultants have evaluated the situation and assessed that Peptonic has strong prospects of being granted the restructuring. Peptonic has applied for corporate restructuring as an exceptional measure to address ongoing liquidity challenges. The Company acknowledges the...

Peptonic Medical AB (publ) ("Peptonic" or the "Company") is adjusting its organization following the structural changes implemented in 2024. As part of this process, the need for financial functions has decreased, and the Company announces that Chief Financial Officer (CFO) Jenni Björnulfson will be leaving her position. Over the past year, Peptonic has carried out strategic changes that have reduced the need for financial resources while shifting focus toward strengthening its commercial operations. In line with these adjustments, the Company has restructured its finance department, leading...

Peptonic Medical (publ) ("Peptonic" or "the Company") announces the launch of VagiVital Intimate Calming Gel, a specially developed product that provides immediate moisture while relieving itching, redness, and irritation in the external genital area. Customer demand for a product tailored to the outer female genitalia has been high. With Intimate Calming Gel, Peptonic meets this demand and, alongside the best-selling VagiVital AktivGel, provides a complete, hormone-free care solution that effectively moisturizes both the internal and external intimate areas. VagiVital Intimate Calming Gel is...